Purdue Seeks To Stop Watson's Reformulated Oxy Generic

Law360, New York (April 25, 2012, 4:59 PM EDT) -- Purdue Pharma LP is once again taking Watson Pharmaceuticals Inc. to court over its plans to market generic OxyContin, filing suit Tuesday in New York federal court to block Watson's attempts to replicate a new version of the blockbuster painkiller.

The complaint alleges that Watson’s abbreviated new drug applications for extended release oxycodone hydrochloride tablets infringe Purdue’s patent for a reformulated version of the drug.

The patent in question, U.S. Patent No. 8,114,383, specifically refers to an “abuse-proofed” form of the drug that is coated in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.